GLP-1 (glucagon-like peptide-1) agonists are therapeutic agents primarily utilized in managing type 2 diabetes, mimicking the action of the endogenous hormone GLP-1, enhancing glucose-dependent insulin secretion and suppressing glucagon release. The gene discussed is GCG; the disease is type 2 diabetes mellitus.